Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18868657 | 0.91 | MAPT (0.45) | MAPTHTTKMT2ARCE1CA1 | |
| SCHEMBL14429286 | 0.84 | KMT2A (0.43) | MAPTHTTKMT2ARCE1CA1 | |
| SCHEMBL1578411 | 0.80 | CA1 (0.45) | HTTKMT2ACA1CA2CA7 | |
| SCHEMBL1578413 | 0.80 | CA1 (0.45) | HTTKMT2ACA1CA2CA7 | |
| SCHEMBL11454462 | 0.76 | CA1 (0.56) | MAPTHTTKMT2ACA1CA2 | |
| SCHEMBL28523703 | 0.76 | HTT (0.48) | MAPTHTTKMT2ACA1CA2 | |
| SCHEMBL18868656 | 0.75 | KMT2A (0.43) | HTTKMT2ACA1CA2CA7 | |
| SCHEMBL15944533 | 0.75 | MAPT (0.47) | MAPTHTTKMT2ARCE1SLC1A1 | |
| SCHEMBL24667576 | 0.75 | CYP2C19 (0.42) | MAPTHTTKMT2ARCE1CYP3A4 | |
| SCHEMBL15944534 | 0.74 | MAPT (0.46) | MAPTHTTKMT2ASLC1A1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3374028-B1 | SPHINGAMIDE COMPOUNDS AND METHODS FOR BINDING INKT CELLS | LA JOLLA INST ALLERGY & IMMUNOLOGY (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10723750-B2 | Sphingamide compounds and methods for binding iNKT cells | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190256541-A1 | SPHINGAMIDE COMPOUNDS AND METHODS FOR BINDING iNKT CELLS | LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723750-B2 | Sphingamide compounds and methods for binding iNKT cells | UGCG, CD4, CERT1 | MAPT 2959/4885HTT 4505/4885KMT2A 603/4885 |
| US-20190256541-A1 | SPHINGAMIDE COMPOUNDS AND METHODS FOR BINDING iNKT CELLS | UGCG, CD4, CERT1 | MAPT 2959/4885HTT 4505/4885KMT2A 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.